DHE (Dihydroergotamine)

DHE became the chemical backbone from which the triptans were derived - Matt Hoffman

DHE (Dihydroergotamine)
DHE (Dihydroergotamine)

image by: HWN

HWN Suggests

Reintroducing DHE for Acute Migraine Treatment

What does the general neurology community need to know about this new attempt at DHE? A clinician may ask, why bother with DHE? We have 7 triptans, so why use this old drug? The answer is that DHE has some very unusual properties that differentiate it from triptans... When patients get pain freedom with DHE, they tend not to have that migraine come back, that is, they tend not to get recurrence. Whereas with triptans, whatever form of triptan they use, recurrence is a significant problem. With injectable sumatriptan, for example, 40% of patients will have the same migraine recur, and have to re-treat. Episodic migraines last 4 to 72 hours, menstrual migraines are even longer, so people often…

read full article

Featured

 DHE - past, present, and future: a narrative review

Dihydroergotamine (DHE) was first approved in 1946 for the acute treatment of migraine. Its efficacy when administered as an intravenous (IV) injection explains its enduring use in the management of migraine today. More recently, attention has been focused on the development of formulations delivered by the inhalational route to either the nasal mucosa or lung with the objective of providing a product that enables easy, needle-free, "at-home" use that is rapidly effective.

Articles of Interest

DHE (dihydroergotamine) and ergotamine

Because ergots can cause serious side effects, they are usually a second- or third-line treatment. Ergots are often reserved as an option for people for whom triptans have failed or have hard-to-treat migraine.

Dihydroergotamine (DHE) – Is there a place for its use?

Nowadays, dihydroergotamine (DHE) is sporadically used as a vasoconstrictor in the treatment of acute migraine. The importance of this drug in medicine has significantly decreased in the recent years. Limitations on the use of dihydroergotamine are due to the high toxicity and increased the risk of severe adverse events after prolonged therapy.

Dihydroergotamine (DHE) – Then and Now: A Narrative Review

Dihydroergotamine was one of the first “synthetic drugs” developed in the 20th century for treating migraine. It is effective and recommended for acute migraine treatment. Since oral DHE is extensively metabolized, it must be given by a non‐oral route. Intravenous DHE requires healthcare personnel to administer, subcutaneous/intramuscular injection is challenging to self‐administer, and the approved nasal spray formulation exhibits low bioavailability and high variability that limits its efficacy. Currently there are several attempts underway to develop non‐oral, non‐injected formulations of DHE.

History of the Use of Ergotamine and Dihydroergotamine in Migraine From 1906 and Onward

DHE was developed in 1943 (35) and tried in migraine on the basis of the belief that migraine headache resulted from an increase in sympathetic activity. Accordingly, DHE was expected to be more efficacious than ergotamine in treating migraine, since it possesses greater α-adrenoceptor activity. However, early clinical experience showed that DHE, although effective in the acute treatment of migraine, must be given in higher doses than ergotamine

stay connected